Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 1,743 trials

Advanced Solid Tumors: M1774 and PLX038 Combination

We are investigating whether a new oral medication combined with another drug can help patients with advanced solid tumors. This study aims to explore the effectiveness of this treatment approach.

Metastatic Triple Negative Breast Cancer>2 yearsSafety phase (I)Oncology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Heart Attack Prevention: Selatogrel Study

We are studying whether self-administering selatogrel can help prevent further heart attacks in individuals with a recent heart attack history. The trial also looks at the safety of this self-administration.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Blood Cancer Treatment: ABBV-319 Study

We are examining how a new intravenous treatment affects adults with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia. The study looks at potential side effects and changes in disease activity.

Follicular LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell Lymphoma>2 yearsSafety phase (I)Oncology

Bacterial Brain Abscess: Oral vs. IV Antibiotics

We are studying whether oral antibiotics are as effective as IV antibiotics for treating bacterial brain abscesses. This trial will help us understand the best treatment options and their impact on recovery and quality of life.

Brain Abscess>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNeurology

Small Bowel Adenocarcinoma: FOLFIRINOX vs. FOLFOX

We are studying two chemotherapy treatments for patients with locally advanced or metastatic small bowel adenocarcinoma. The goal is to find out which treatment helps patients live longer without their cancer worsening.

Small Bowel Adenocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Acyclovir for ICU Patients with Herpes Simplex Virus Reactivation

We are studying whether acyclovir can help reduce mortality and improve recovery in intubated patients with Herpes simplex virus reactivation. This trial compares acyclovir to a placebo to see which treatment is more effective.

Herpes Simplex Reactivation>2 yearsConfirmation phase (III)Standard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: Comparing Conditioning Regimens in Children

We are studying two different treatment plans for children with Acute Myeloid Leukemia undergoing stem cell transplants. Our goal is to find out which plan leads to better survival and fewer side effects.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

Multiple Myeloma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Metastatic Colorectal Cancer: LB-100 and Atezolizumab Study

We are investigating a new combination of medications for patients with metastatic colorectal cancer to see if it is safe and effective. This study aims to find the best dose and understand how well the treatment works.

Microsatellite Stable Colorectal Cancer>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

CALR-Mutated Myeloproliferative Neoplasms: JNJ-88549968 Study

We are testing a new T-cell redirecting antibody for patients with CALR-mutated myeloproliferative neoplasms. This study aims to evaluate its safety and potential effectiveness in treating this condition.

CALR-mutated Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology

Carcinoma of Unknown Primary: [18F]F-FAPI PET-CT Study

We are investigating whether [18F]F-FAPI PET-CT can help identify the primary tumor in patients with carcinoma of unknown primary. This study aims to improve diagnosis and treatment options for these patients.

Carcinoma of Unknown Primary>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Kidney Cancer: New Treatment Study

We are investigating a new treatment option for individuals diagnosed with kidney cancer. The goal is to see if this treatment can improve outcomes compared to standard care.

Metastatic Renal Cell Carcinoma with End-Stage Renal Disease>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Trastuzumab Deruxtecan (T-DXd) for Unresectable or Metastatic HER2-low Breast Cancer

We are studying the effects of T-DXd in patients with hormone receptor-negative and hormone receptor-positive HER2-low breast cancer. The goal is to see if it can improve treatment outcomes compared to current options.

Advanced Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Metastatic Neuroendocrine Prostate Cancer: Targeted Radioligand Therapy

We are exploring a new targeted treatment for patients with metastatic neuroendocrine prostate cancer. This study aims to assess its safety and effectiveness compared to existing therapies.

Metastatic Neuroendocrine Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology